Literature DB >> 24475576

Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance.

M Shimada1, R Nishimura2, M Hatae3, M Hiura4, K Takehara5, T Tase6, H Yamada7, H Kurachis8, T Sugiyama9, J Kigawa10.   

Abstract

PURPOSE: The authors conducted this retrospective study to evaluate the efficacy of radiotherapy (RT) for high-risk patients with adenocarcinoma (AC) compared with chemotherapy (CT) after radical hysterectomy.
MATERIALS AND METHODS: There were 263 patients with AC and 58 with adenosquamous cell carcinoma (ASCC). Of these 321 patients, 151 received adjuvant treatment. Of these 151 patients, 69 received radiotherapy (RT) alone, including concurrent chemoradiotherapy (CCRT) with weekly cisdiamminedichloroplatinum (CDDP), 64 patients received CT alone, and 18 patients received concomitant RT and CT (RT + CT).
RESULTS: The five-year overall survival (OS) was 70.9% for patients receiving RT, 79.2% for CT, and 66.2% for RT + CT. Adjuvant treatment did not affect the incidence or the pattern of recurrence. The incidence of lymph node involvement was 9.0% in Stage Ib1, 23.9% in Stage Ib2, 30.8% in Stage IIa, and 41.2% in Stage IIb.
CONCLUSIONS: Adjuvant CT may be effective for high-risk patients with cervical adenocarcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 24475576

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  8 in total

1.  Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan.

Authors:  Hideki Tokunaga; Toru Nakanishi; Takashi Iwata; Daisuke Aoki; Toshiaki Saito; Satoru Nagase; Fumiaki Takahashi; Nobuo Yaegashi; Yoh Watanabe
Journal:  Int J Clin Oncol       Date:  2014-07-16       Impact factor: 3.402

2.  Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Okame; Atsumi Kojima; Norihiro Teramoto; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara; Takayoshi Nogawa
Journal:  Int J Clin Oncol       Date:  2015-12-22       Impact factor: 3.402

3.  The baseline recurrence risk of patients with intermediate-risk cervical cancer.

Authors:  Yutaka Yoneoka; Mayumi Kobayashi Kato; Yasuhito Tanase; Masaya Uno; Mitsuya Ishikawa; Takashi Murakami; Tomoyasu Kato
Journal:  Obstet Gynecol Sci       Date:  2021-01-08

4.  Cervical Cancer Recurrence and Patient Survival After Radical Hysterectomy Followed by Either Adjuvant Chemotherapy or Adjuvant Radiotherapy With Optional Concurrent Chemotherapy: A Systematic Review and Meta-Analysis.

Authors:  Yu-Fei Zhang; Yu Fan; Peng Zhang; Jia-Ying Ruan; Yi Mu; Jin-Ke Li
Journal:  Front Oncol       Date:  2022-03-04       Impact factor: 6.244

5.  Biology and treatment of cervical adenocarcinoma.

Authors:  Satoshi Takeuchi
Journal:  Chin J Cancer Res       Date:  2016-04       Impact factor: 5.087

6.  Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors.

Authors:  Hao Yu; Linlin Zhang; Xuelian Du; Xiugui Sheng
Journal:  Onco Targets Ther       Date:  2016-12-01       Impact factor: 4.147

7.  Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis.

Authors:  Kwang Beom Lee; Seung Hyuk Shim; Jong Min Lee
Journal:  J Gynecol Oncol       Date:  2018-04-16       Impact factor: 4.401

8.  Phase 1/2 study of concurrent chemoradiotherapy with weekly irinotecan hydrochloride for advanced/recurrence uterine cancer: A multi-institutional study of Kansai Clinical Oncology Group.

Authors:  Satoshi Takeuchi; Haruo Kuroboshi; Taisuke Mori; Kimihiko Ito; Eiji Kondo; Tsutomu Tabata; Yoshio Itani; Ryuji Kawaguchi; Kyosuke Takeuchi; Toshinori Soejima; Ryohei Sasaki
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.